Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of cenegermin (OXERVATE(®), Dompé) to submit evidence for the clinical and cost effectiveness of cenegermin for neurotrophic keratitis (NK). The Liverpool R...

詳細記述

保存先:
書誌詳細
出版年:Pharmacoecon Open
主要な著者: Fleeman, Nigel, Mahon, James, Nevitt, Sarah, Duarte, Rui, Boland, Angela, Kotas, Eleanor, Dundar, Yenal, McEntee, Joanne, Ahmad, Sajjad
フォーマット: Artigo
言語:Inglês
出版事項: Springer International Publishing 2019
主題:
Review Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861391/
https://ncbi.nlm.nih.gov/pubmed/31240690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-0138-z
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料